|
1
|
Bruix J and Sherman M; American
Association for the Study of Liver Diseases. Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Curado M, Edwards B and Shin H: Cancer
Incidence in Five Continents. IARC Sci Publ; Lyon: 2007
|
|
3
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
4
|
Okuda K: Hepatocellular carcinoma. J
Hepatol. 32(Suppl): 225–237. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cammà C, Schepis F, Orlando A, Albanese M,
Shahied L, Trevisani F, Andreone P, Craxì A and Cottone M:
Transarterial chemoembolization for unresectable hepatocellular
carcinoma: Meta-analysis of randomized controlled trials.
Radiology. 224:47–54. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Llovet JM, Real MI, Montaña X, Planas R,
Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, et al;
Barcelona Liver Cancer Group. Arterial embolisation or
chemoembolisation versus symptomatic treatment in patients with
unresectable hepatocellular carcinoma: A randomised controlled
trial. Lancet. 359:1734–1739. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maluccio MA, Covey AM, Porat LB, Schubert
J, Brody LA, Sofocleous CT, Getrajdman GI, Jarnagin W, Dematteo R,
Blumgart LH, et al: Transcatheter arterial embolization with only
particles for the treatment of unresectable hepatocellular
carcinoma. J Vasc Interv Radiol. 19:862–869. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Saharinen P, Eklund L, Pulkki K, Bono P
and Alitalo K: VEGF and angiopoietin signaling in tumor
angiogenesis and metastasis. Trends Mol Med. 17:347–362. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu W, Kwon JH, Moon YH, Kim YB, Yu YS, Lee
N, Choi KY, Kim YS, Park YK, Kim BW, et al: Influence of
preoperative transcatheter arterial chemoembolization on gene
expression in the HIF-1α pathway in patients with hepatocellular
carcinoma. J Cancer Res Clin Oncol. 140:1507–1515. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dai CX, Gao Q, Qiu SJ, Ju MJ, Cai MY, Xu
YF, Zhou J, Zhang BH and Fan J: Hypoxia-inducible factor-1 alpha,
in association with inflammation, angiogenesis and MYC, is a
critical prognostic factor in patients with HCC after surgery. BMC
Cancer. 9:4182009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Semenza GL: Hypoxia-inducible factor 1:
Oxygen homeostasis and disease pathophysiology. Trends Mol Med.
7:345–350. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Valencak J, Kittler H, Schmid K, Schreiber
M, Raderer M, Gonzalez-Inchaurraga M, Birner P and Pehamberger H:
Prognostic relevance of hypoxia inducible factor-1 alpha expression
in patients with melanoma. Clin Exp Dermatol. 34:e962–e964. 2009.
View Article : Google Scholar
|
|
13
|
Hirota K: Hypoxia-inducible factor 1, a
master transcription factor of cellular hypoxic gene expression. J
Anesth. 16:150–159. 2002. View Article : Google Scholar
|
|
14
|
Klatte T, Seligson DB, Riggs SB, Leppert
JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ and
Belldegrun AS: Hypoxia-inducible factor 1 alpha in clear cell renal
cell carcinoma. Clin Cancer Res. 13:7388–7393. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miyoshi A, Kitajima Y, Ide T, Ohtaka K,
Nagasawa H, Uto Y, Hori H and Miyazaki K: Hypoxia accelerates
cancer invasion of hepatoma cells by upregulating MMP expression in
an HIF-1 alpha-independent manner. Int J Oncol. 29:1533–1539.
2006.PubMed/NCBI
|
|
16
|
Wu XZ, Xie GR and Chen D: Hypoxia and
hepatocellular carcinoma: The therapeutic target for hepatocellular
carcinoma. J Gastroenterol Hepatol. 22:1178–1182. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marnett LJ: Cyclooxygenase mechanisms.
Curr Opin Chem Biol. 4:545–552. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Smith WL, DeWitt DL and Garavito RM:
Cyclooxygenases: Structural, cellular, and molecular biology. Annu
Rev Biochem. 69:145–182. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang D and Dubois RN: Prostaglandins and
cancer. Gut. 55:115–122. 2006. View Article : Google Scholar
|
|
20
|
Yang Y, Zhu J, Gou H, Cao D, Jiang M and
Hou M: Clinical significance of Cox-2, Survivin and Bcl-2
expression in hepatocellular carcinoma (HCC). Med Oncol.
28:796–803. 2011. View Article : Google Scholar
|
|
21
|
Erdem H, Gündogdu C and Sipal S:
Correlation of E-cadherin, VEGF, COX-2 expression to prognostic
parameters in papillary thyroid carcinoma. Exp Mol Pathol.
90:312–317. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Raspollini MR, Amunni G, Villanucci A,
Boddi V, Baroni G, Taddei A and Taddei GL: Expression of inducible
nitric oxide synthase and cyclooxygenase-2 in ovarian cancer:
Correlation with clinical outcome. Gynecol Oncol. 92:806–812. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shi H, Xu JM, Hu NZ and Xie HJ: Prognostic
significance of expression of cyclooxygenase-2 and vascular
endothelial growth factor in human gastric carcinoma. World J
Gastroenterol. 9:1421–1426. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Karray-Chouayekh S, Trifa F, Khabir A,
Boujelbene N, Sellami-Boudawara T, Daoud J, Frikha M, Gargouri A
and Mokdad-Gargouri R: Methylation status and overexpression of
COX-2 in Tunisian patients with ductal invasive breast carcinoma.
Tumour Biol. 32:461–468. 2011. View Article : Google Scholar
|
|
25
|
Lim SC, Lee TB, Choi CH, Ryu SY, Min YD
and Kim KJ: Prognostic significance of cyclooxygenase-2 expression
and nuclear p53 accumulation in patients with colorectal cancer. J
Surg Oncol. 97:51–56. 2008. View Article : Google Scholar
|
|
26
|
Shamma A, Yamamoto H, Doki Y, Okami J,
Kondo M, Fujiwara Y, Yano M, Inoue M, Matsuura N, Shiozaki H, et
al: Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of
the esophagus. Clin Cancer Res. 6:1229–1238. 2000.PubMed/NCBI
|
|
27
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Copple BL: Hypoxia stimulates hepatocyte
epithelial to mesenchymal transition by hypoxia-inducible factor
and transforming growth factor-beta-dependent mechanisms. Liver
Int. 30:669–682. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miladi-Abdennadher I, Abdelmaksoud-Dammak
R, Ayed-Guerfali DB, Ayadi L, Khabir A, Amouri A, Frikha F, Tahri
N, Ellouz S, Frikha M, et al: Expression of COX-2 and E-cadherin in
Tunisian patients with colorectal adenocarcinoma. Acta Histochem.
114:577–581. 2012. View Article : Google Scholar
|
|
31
|
Zhang YB, Wang X, Meister EA, Gong KR, Yan
SC, Lu GW, Ji XM and Shao G: The effects of CoCl2 on
HIF-1α protein under experimental conditions of autoprogressive
hypoxia using mouse models. Int J Mol Sci. 15:10999–11012. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ and
Cao GW: Increased expression of vascular endothelial growth factor
in hepatocellular carcinoma after transcatheter arterial
chemoembolization. Acta Radiol. 49:523–529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Semenza GL: Hypoxia-inducible factors:
Mediators of cancer progression and targets for cancer therapy.
Trends Pharmacol Sci. 33:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang MH, Wu MZ, Chiou SH, Chen PM, Chang
SY, Liu CJ, Teng SC and Wu KJ: Direct regulation of TWIST by HIF-1
alpha promotes metastasis. Nat Cell Biol. 10:295–305. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kaidi A, Qualtrough D, Williams AC and
Paraskeva C: Direct transcriptional up-regulation of
cyclooxygenase-2 by hypoxiainducible factor (HIF)-1 promotes
colorectal tumor cell survival and enhances HIF-1 transcriptional
activity during hypoxia. Cancer Res. 66:6683–6691. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schmedtje JF Jr, Ji YS, Liu WL, DuBois RN
and Runge MS: Hypoxia induces cyclooxygenase-2 via the NF-kappaB
p65 transcription factor in human vascular endothelial cells. J
Biol Chem. 272:601–608. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hashiguchi M, Ueno S, Sakoda M, Iino S,
Hiwatashi K, Minami K, Ando K, Mataki Y, Maemura K, Shinchi H, et
al: Clinical implication of ZEB-1 and E-cadherin expression in
hepatocellular carcinoma (HCC). BMC Cancer. 13:5722013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu S, Kumar SM, Martin JS, Yang R and Xu
X: Snail1 mediates hypoxia-induced melanoma progression. Am J
Pathol. 179:3020–3031. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Woo HY, Min AL, Choi JY, Bae SH, Yoon SK
and Jung CK: Clinicopathologic significance of the expression of
Snail in hepatocellular carcinoma. Korean J Hepatol. 17:12–18.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shirahata A, Sakata M, Sakuraba K, Goto T,
Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, et
al: Vimentin methylation as a marker for advanced colorectal
carcinoma. Anticancer Res. 29:279–281. 2009.PubMed/NCBI
|
|
41
|
Shi Y, Wu H, Zhang M, Ding L, Meng F and
Fan X: Expression of the epithelial-mesenchymal transition-related
proteins and their clinical significance in lung adenocarcinoma.
Diagn Pathol. 8:892013. View Article : Google Scholar : PubMed/NCBI
|
